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Ribavirin is effective for treating immunocompromised patients 
with chronic hepatitis E virus infection. However, ribavirin 
treatment is not always successful. We describe 3 solid organ 
transplant recipients treated with sofosbuvir and ribavirin after 
failing ribavirin monotherapy. Complete elimination of hepa-
titis E virus could not be achieved.
Keywords.  chronic hepatitis E; sofosbuvir; solid organ 
transplant recipients.
Hepatitis E virus (HEV) genotype 3 is a common cause of 
acute viral hepatitis in the Netherlands [1]. In general, immu-
nocompetent patients with HEV infection are able to clear the 
virus spontaneously. However, immunocompromised patients 
develop chronic infection in approximately 60% of cases (de-
fined as HEV ribonucleic acid [RNA] detectable in plasma for 
more than 3 months), which may lead to liver fibrosis and cir-
rhosis. Reduction of immunosuppression, if possible, is the 
first step in the treatment of chronic HEV infection and results 
in viral clearance in approximately one third of patients. The 
second-line treatment, with ribavirin monotherapy, can lead to 
a sustained virological response (SVR) in 78% of patients and 
85% after retreatment. For solid organ transplant (SOT) re-
cipients who fail to achieve SVR on ribavirin therapy, alterna-
tive treatment options are scarce [2]. Liver transplant patients 
may benefit from pegylated-interferon (PEG-IFN) therapy, but 
PEG-IFN is contraindicated after other SOTs, because of the in-
creased risk of allograft rejection [3, 4].
Sofosbuvir in combination with other antiviral agents is ap-
proved by the US Food and Drug Administration to treat chronic 
hepatitis C virus (HCV) infection [5]. It has been shown that 
sofosbuvir can inhibit HEV genotype 3 replication in vitro and 
has an additive effect when combined with ribavirin [6]. Thus 
far, the clinical effect of sofosbuvir in chronic HEV infections is 
unclear. A multicenter trial for the treatment of chronic HEV 
with sofosbuvir is ongoing (EudraCT Number 2017-000403-
24), but results have not yet been reported. Until now, sofosbuvir 
treatment for chronic HEV infection has been described in 6 
patients. Two liver transplant recipients with a HCV and HEV 
coinfection were treated with sofosbuvir and daclatasvir. In 1 
patient, this therapy regimen was not effective in clearing the 
chronic HEV infection, whereas in the other patient both HCV 
and HEV were cleared after 12 weeks of treatment; this latter 
patient was also treated with ribavirin [7, 8]. Four additional 
cases of ribavirin plus sofosbuvir therapy for chronic HEV in-
fections have been described. In 3 of these 4 cases an antiviral 
effect was observed; however, SVR was not achieved [9–11]. In 
the last, most recently described case report, HEV was cleared 
after 3 months of ribavirin plus sofosbuvir treatment [12].
We describe 3 SOT recipients with chronic HEV infection, 
who initially failed to respond to ribavirin monotherapy and 
were retreated with a combination of sofosbuvir and ribavirin. 
Informed consent for publication was obtained for all patients.
CASE DESCRIPTION
Patient 1, a 25-year-old male, required a heart transplantation 
in 2012 because of end-stage heart failure caused by a cardio-
myopathy. In 2015, he was diagnosed with a HEV genotype 3c 
infection with elevated alanine aminotransferase (ALT) levels 
(Figure 1A). Reduction of immunosuppression (consisting of 
mycophenolate mofetil bid 1000 mg and tacrolimus bid 5 mg) 
was not possible because of the risk of allograft rejection in 
this patient who had suffered a previous episode of threatened 
rejection. Therefore, treatment with ribavirin 600  mg qd was 
initiated. After 3 months of treatment, ALT levels returned to 
normal and HEV RNA became undetectable in plasma, but not 
in feces. Therefore, ribavirin therapy was continued. One year 
after diagnosis, HEV RNA relapsed in plasma. The ribavirin 
dose was increased to 400 mg bid and subsequently to 600 mg 
bid (ribavirin plasma levels varied from 1.5 to 2.1  mg/L). 
Despite this intensification of therapy, HEV RNA remained de-
tectable in plasma. By means of sequence analysis of ORF1, a 
previously described mutation [13, 14] was detected (G1634R). 
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Fibroscan showed no signs of liver fibrosis. Sofosbuvir 400 mg 
qd was added to the treatment in May 2017. After 1 month of 
treatment, HEV RNA in plasma became undetectable. Hepatitis 
E virus RNA remained detectable in feces, but cycle threshold 
values increased from 25 to 30, possibly suggesting a response 
to treatment. After 24 weeks of combined treatment, HEV RNA 
was still detected in feces without further improvement, and 
therefore sofosbuvir and ribavirin were stopped. Two weeks 
Time course of  patient 1
Time course of  patient 2
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Figure 1. Graphs indicate the following: therapeutic interventions, hepatitis E virus (HEV) plasma and fecal load, alanine aminotransferase (ALT) levels, ribavirin levels, 
sirolimus/tacrolimus levels, and presence of mutations. (x-axis) Time from diagnosis of HEV infection. (y-axis, left) Hepatitis E virus plasma load (green), ribavirin levels (red), 
and sirolimus/tacrolimus levels (black). (y-axis, right) Alanine aminotransferase level (blue). Sofosbuvir treatment is indicated by the gray box. Ribavirin dosing changes are 
shown by the black arrows and the thickness of the line. In the boxes below the graphs, the presence of HEV RNA in feces is depicted, expressed in cycle threshold (Ct) values. 
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later, HEV RNA load in plasma and feces relapsed to baseline 
levels as expected [15]. Currently, the patient still has a detect-
able HEV load in plasma and elevated ALT levels. Fibroscan 
shows no signs of fibrosis.
Patient 2, a 64-year-old woman, underwent a bilateral lung 
transplantation in January 2000 because of severe emphysema 
caused by alpha-1-antitripsin deficiency. In 2017, she had el-
evated ALT levels and was diagnosed with a HEV infection, 
genotype 3c (Figure 1B). The intensity of immunosuppres-
sive therapy (consisting of mycophenolate mofetil 500 mg bid, 
tacrolimus 2.5 mg bid, and prednisolone 5 mg qd) could only be 
modestly reduced (tacrolimus decreased to 2 mg bid) because 
of prior signs of rejection. Treatment with ribavirin 600 mg qd 
was initiated. After 3 months of treatment, HEV RNA load in 
plasma was undetectable, but feces remained positive. Therefore, 
the ribavirin dose was increased to 600 mg bid, which did not 
result in fecal clearance of the virus either (ribavirin plasma 
levels ranged from 0.8 to 3.8 mg/L). Two previously described 
mutations [13, 14] were detected (K1383N and G1634R). After 
more than 7 months of ribavirin treatment, sofosbuvir 400 mg 
qd was added and the ribavirin dose was decreased to 600 mg 
qd because of side effects (hemoglobin [Hb] decreased by 
2 mmol/L to a nadir of 7.2 mmol/L). Feces remained HEV-RNA 
positive after 8 weeks of combined treatment, and sofosbuvir 
was stopped after 12 weeks of therapy. Ribavirin was stopped 
2 months later. Subsequently, as expected, HEV RNA relapsed 
in plasma. Four months later, HEV RNA spontaneously became 
undetectable in plasma and feces, without any modulation of 
immunosuppressive therapy, and remained as such up until 
today (9 months later).
Patient 3, a 52-year-old woman, underwent a bilateral lung 
transplantation in 2011 because of restrictive lung disease 
caused by chemoradiation therapy in childhood. In February 
2017, elevated ALT levels were observed and HEV RNA was de-
tected in plasma (Figure 1C). In hindsight, ALT levels had been 
elevated since transplantation, and a plasma sample 6 months 
earlier (September 2016)  was tested positive for HEV RNA, 
which confirmed the diagnosis of chronic HEV gt3 infection. 
Fibroscan revealed stage F4 fibrosis. Immunosuppressive treat-
ment consisted of sirolimus 2  mg qd, mycophenolate mofetil 
750 mg bid, and prednisolone 7.5 mg qd. Immunosuppression 
was not reduced at first due to fear of rejection; the restricted 
anatomical space only allowed transplantation of the lower 
lobes resulting in a total lung capacity of 2.2 liters of air, and she 
remained dependent on intermittent noninvasive ventilation 
after lung transplantation. Ribavirin treatment was initiated 
(400 mg bid). Hepatitis E virus RNA load in plasma decreased 
but remained detectable at low levels. The ALT levels returned to 
normal range. Five months after start of treatment, the dose was 
reduced to 200 mg bid, because of high ribavirin levels (up to 
4.2 mg/L) and significant anemia (Hb decreased by 2.5 mmol/L 
to a nadir of 6.3 mmol/L). One month later, immunosuppressive 
treatment could be reduced (mycophenolate mofetil was 
lowered to 500  mg bid). After 7  months of ribavirin therapy, 
HEV RNA remained detectable in plasma. As salvage treatment, 
sofosbuvir was added to the ribavirin regimen. After 8 weeks of 
combination therapy, no antiviral response was observed and 
the treatment with ribavirin and sofosbuvir was stopped. Three 
months later, HEV RNA was detected in plasma at pretreatment 
levels. After 6 months, ALT levels increased up to 146 U/L and 
the patient developed decompensated liver cirrhosis.
DISCUSSION
We describe 3 SOT recipients who were treated with a combi-
nation of sofosbuvir and ribavirin for chronic HEV infection, 
because SVR was not achieved with ribavirin monotherapy. 
Two of 3 patients showed partial antiviral response to treat-
ment, but complete clearance of the virus was not observed. 
After treatment was stopped, HEV-RNA plasma levels returned 
to pretreatment levels, suggesting an antiviral activity of the 
sofosbuvir plus ribavirin combination.
The sofosbuvir treatment length varied in these patients, 
ranging from 8 to 24 weeks. Even after a long treatment period 
of 24 weeks, HEV remained detectable at low levels and was 
not cleared from the feces. This is in line with the findings of 
Valk et al [9] and Fraga et al [11], by whom an antiviral effect of 
sofosbuvir was observed; however, SVR was not achieved.
All patients were treated with a sofosbuvir dose of 400 mg 
qd, in analogy to treatment of HCV infections. Because the 
anti-HEV activity of sofosbuvir has been shown to be less 
pronounced than the anti-HCV activity in vitro [6], a higher 
dose might be needed to achieve complete HEV elimination. 
However, higher dosing is not registered and the safety of this 
is unknown.
The success of sofosbuvir treatment may also be dependent on 
the combined effect with ribavirin [6]. In our patients, ribavirin 
monotherapy failed, which may have compromised the effec-
tiveness of the combination therapy. Nevertheless, ribavirin will 
remain the first-line therapy, and sofosbuvir would only be in-
dicated in those who fail ribavirin monotherapy.
In all 3 patients, ribavirin plasma levels were measured; how-
ever, the optimal ribavirin plasma level and effect on SVR in 
HEV is unclear [16]. Two patients showed mutations that have 
been found in other patients with ribavirin treatment failure 
[13, 14], but the impact of these variants on HEV treatment out-
come is yet debatable [4, 15].
Although the antiviral effect of sofosbuvir in vitro was prom-
ising, it seems that in patients with chronic HEV infection who 
failed on ribavirin monotherapy and for whom reduction of im-
munosuppressive medication or treatment with PEG-IFN is not 
an option, the above-mentioned addition of sofosbuvir to ribavirin 
treatment may not be the salvage therapy we hoped for, in spite 
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12]. The liver transplant recipient with clearance of HEV under 
sofosbuvir plus ribavirin treatment had a concurrent HCV in-
fection [8]. In theory, the treatment of HCV may have triggered 
an immunological response that induced HEV clearance as well. 
Another explanation may be that the ribavirin was the effective 
agent in clearing the HEV infection in this patient, because he had 
not been treated with ribavirin monotherapy before.
Methods
Our methods for quantitative real-time polymerase chain re-
action and sequencing analysis for HEV genotyping are based 
on Zhao et al [17], Wang et al [18], van der Poel et al [19], and 
Baylis et al [20].
CONCLUSIONS
In conclusion, sofosbuvir showed variable antiviral ac-
tivity against HEV but did not result in SVR in our patients. 
Alternative treatment options are urgently needed for SOT re-
cipients with chronic HEV infection failing ribavirin treatment 
and being at risk for progression of liver fibrosis leading to cir-
rhosis and, in some cases, decompensation and death.
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